GRANGE DAVID L 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Mar 1, 2010
Insider Transaction Report
Form 4
GRANGE DAVID L
DirectorChief Executive Officer
Transactions
- Award
Stock Options (to buy)
2010-02-25+100,000→ 100,000 totalExercise: $21.17From: 2011-02-25Exp: 2020-02-25→ Common Stock (100,000 underlying)
Holdings
- 61,045
Common Stock
- 200,000
Stock Options (to buy)
Exercise: $22.75From: 2010-07-01Exp: 2019-07-01→ Common Stock (200,000 underlying) - 6,265
Stock Options (to buy)
Exercise: $42.77From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,265 underlying)
Footnotes (3)
- [F1]50,000 shares of restricted stock were granted upon the Reporting Person's acceptance of employment as Chief Executive Officer. These shares vest in four equal increments on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.
- [F2]The options vest in three equal installments on 2/25/11, 2/25/12 and 2/25/13.
- [F3]The options vest in four equal installments of 50,000 on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.